Nonlinear dynamics of CAR-T cell therapy

被引:0
|
作者
Fassoni, Artur C. [1 ,2 ]
Braga, Denis C. [1 ]
机构
[1] Univ Fed Itajuba, Inst Matemat & Computacao, BR-37500903 Itajuba, Brazil
[2] Tech Univ Dresden, Inst Med Informat & Biometry, Dresden, Germany
关键词
Nonlinear phenomena; Differential equations; Hopf bifurcation; Bogdanov-Takens bifurcation; Mathematical oncology; Immunotherapy; MODELS; PROLIFERATION; BIFURCATIONS; OSCILLATIONS;
D O I
10.1016/j.chaos.2024.115871
中图分类号
O1 [数学];
学科分类号
0701 ; 070101 ;
摘要
Chimeric antigen receptor T-cell (CAR-T) therapy is considered a promising cancer treatment. The dynamic response to this therapy can be broadly divided into a short-term phase, ranging from weeks to months, and a long-term phase, ranging from months to years. While the short-term response, encompassing the multiphasic kinetics of CAR-T cells, is better understood, the mechanisms underlying the outcomes of the long-term response, characterized by sustained remission, relapse, or disease progression, remain less understood due to limited clinical data. Here, we analyze the long-term dynamics of a previously validated mathematical model of CAR-T cell therapy. We perform a comprehensive stability and bifurcation analysis, examining model equilibria and their dynamics over the entire parameter space. Our results show that therapy failure results from a combination of insufficient CAR-T cell proliferation and increased tumor immunosuppression. By combining different techniques of nonlinear dynamics, we identify Hopf and Bogdanov-Takens bifurcations, which allow to elucidate the mechanisms behind oscillatory remissions and transitions to tumor escape. In particular, rapid expansion of CAR-T cells leads to oscillatory tumor control, while increased tumor immunosuppression destabilizes these oscillations, resulting in transient remissions followed by relapse. Our study highlights different mathematical tools to study nonlinear models and provides critical insights into the nonlinear dynamics of CAR-T therapy arising from the complex interplay between CAR-T cells and tumor cells.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Engineering strategies to mitigate toxicities associated with CAR-T cell therapy
    Wolter, Tyler
    Wang, Yixin
    Hu, Quanyin
    BMEMAT, 2024,
  • [42] Evaluation of Toxicity Associated with CAR-T Cell Therapy and Nursing Interventions
    Erdal, Seckin
    Kuni, Aysem
    Selcuk, Sevinc
    Can, Gulbeyaz
    BEZMIALEM SCIENCE, 2024, 12 (04): : 470 - 478
  • [43] Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
    Hao Wang
    Gurbakhash Kaur
    Alexander I. Sankin
    Fuxiang Chen
    Fangxia Guan
    Xingxing Zang
    Journal of Hematology & Oncology, 12
  • [44] Mesothelin-targeted CAR-T cell therapy for solid tumors
    Klampatsa, Astero
    Dimou, Vivian
    Albelda, Steven M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 473 - 486
  • [45] CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?
    Cutri-French, Clare
    Nasioudis, Dimitrios
    George, Erin
    Tanyi, Janos L.
    DIAGNOSTICS, 2024, 14 (08)
  • [46] Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy
    Dabas, Preeti
    Danda, Adithi
    MEDICAL ONCOLOGY, 2023, 40 (09)
  • [47] Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy
    Jenkins, Yasmin
    Zabkiewicz, Joanna
    Ottmann, Oliver
    Jones, Nicholas
    ANTIBODIES, 2021, 10 (02)
  • [48] CAR-T cell therapy in ovarian cancer: from the bench to the bedside
    Zhu, Xinxin
    Cai, Han
    Zhao, Ling
    Ning, Li
    Lang, Jinghe
    ONCOTARGET, 2017, 8 (38) : 64607 - 64621
  • [49] The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
    Zhao, Zijun
    Chen, Yu
    Francisco, Ngiambudulu M.
    Zhang, Yuanqing
    Wu, Minhao
    ACTA PHARMACEUTICA SINICA B, 2018, 8 (04) : 539 - 551
  • [50] Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy
    Preeti Dabas
    Adithi Danda
    Medical Oncology, 40